Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a Healthcare company (Biotechnology) with a market capitalization of $479M. The Maz Rating grades it against the other companies in its sector.
Fennec Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.58, Fennec Pharmaceuticals Inc. trades at 582.9x trailing earnings, 7.1x sales and 9.5x book value, with an EV/EBITDA of 161.9. Over the last twelve months it generated about $68M of revenue and $822552 of net income. It runs a gross margin of 94.1%, an operating margin of 5.6% and a net margin of 3.1%. It shows return on equity of 4.9%, return on invested capital of 4.2% and a free cash flow yield of 0.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 6.11. Over the past 52 weeks the share price ranged from $5.65 to $13.64, with a beta of 1.21.
Fennec Pharmaceuticals Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.